Disability progression over 10 years in people with relapsing-remitting multiple sclerosis (MS) is slower than previously thought, according to a study published in the European Journal of Neurology.
The same was not true for people with progressive-onset MS, reported Anne Kerbrat, MD, of University Hospital in Rennes, France, and colleagues.
The researchers followed a population-based cohort that showed first clinical onset of MS symptoms at time of first approved disease modifying drug between 2000 and 2001. Relapses, treatments, and disability were then recorded up to 10 years after onset.
The study included 278 patients, 244 of which had attack-onset MS and 34 with progressive-onset. Over the course of the study, 30% of patients with relapsing-remitting MS continued with clinically isolated syndrome and 70% had a second relapse after a median time of 1.7 years. Eighty percent of the group received disease modifying drugs for at least six months, 29% reached disability status scale 3 and 8% reached disability status scale 6.
All patients with progressive-onset MS reached disability status scale 3, and 59% reached disability status scale 6.
The researchers suggest that the differences observed in disability prognosis be translated into clinical practice.
Multiple sclerosis (MS) prognosis remains a challenge for both patients and physicians. Complementary to natural history studies, updated population-based data from the first event suggestive of MS, at the time of the first approved disease modifying drug (DMD), are needed. Our objective was to provide a 10-year history of MS from clinical onset at time of first approved DMDs in a population-based cohort.
A population-based cohort of patients whose first clinical event suggestive of MS had occurred in Brittany between 2000 and 2001 was prospectively selected. History of relapses, treatments and disability up to 10 years after onset were collected.